Comprehensive Library Of Resveratrol News

They die, one every minute.

A sudden blockage of blood circulation in one or more coronary arteries results in damage to heart muscle that many cannot survive.

They represent as many as 1 in every 6 deaths in the U.S.

They are American adults whose lives should have been saved but weren’t.

There are 16 million of them at high risk who have been diagnosed with coronary artery disease.

The baby aspirin tablets, the statin cholesterol-lowering drugs, the streptokinase clot busters and inserted catheter balloons that break up clots in coronary arteries aren’t saving as many lives as advertised. Baby aspirin doesn’t sufficiently inhibit clots in heart arteries and a standard aspirin tablet induces bleeding gastric ulcers that can be mortal in themselves.

Read the whole post »

So why is resveratrol averting mortal heart attacks in the animal lab, in preliminary studies restoring vision to humans who are battling an otherwise hopeless eye disease, and is considered to be the most promising anti-cancer molecule on the planet — and therefore addresses the three most feared health problems of humanity — yet relatively few Americans have adopted res-pills into their daily health regimens?

These questions and more are answered by Bill Sardi in his most recent e-book THE CASE FOR RESVERATROL: Why Aren’t More Americans Taking Resveratrol Pills?

Read the whole post »

Sirtris’ re-emergence with its Sirtuin1-gene activating SRT1720 drug gains the attention of the pharma world and health seekers. Most striking was that high-fat-fed mice did not gain weight, something that was only demonstrated in rodents with a supra-high dose of resveratrol (21,000 mg human equivalent dose). However, to produce this effect and overcome fatty liver SRT1720 had to be given in a 100 mg/kilogram dose, equivalent in human terms to 7000 mg for a 160-lb human. I’m not sure healthy humans are going to want to take seven 1000 mg pills a day, and at what cost? Lower dose (2100 mg human equivalent dose) SRT1720 produced a much more tempered effect and a modest improvement in life span. So maybe humans who are killing themselves by eating high-fat diets would benefit from this drug, but maybe not healthy people. Recognize the lab mice in this experiment were fed a 60% fat-calorie diet whereas humans generally consume 20-25% fat calorie diets. As a scientific achievement, SRT1720 is notable, but it doesn’t yet translate into a practical or affordable medicine for humans. The claim was these so-called new chemical entities under development by Sirtris were 1000-fold more powerful than resveratrol, but the dose required to produce a 44% increase in life span (about what a limited calorie diet achieves) is still quite high. And while there were no signficant side effects, this was true for mega-dose resveratrol in animal models of treatment for multiple myeloma (bone marrow cancer), but when 5000 mg of resveratrol was given to humans with this type of cancer it rapidly induced kidney failure. Bottom line, SRT1720 is a scientific achievement that is a long way from becoming an anti-aging drug. – Bill Sardi, ResveratrolNews.com

Read the whole post »

The announcement today, published in The New York Times, that a synthetic drug, SRT1720, produced by Sirtris Pharmaceuticals, mimics resveratrol and overcomes fatty liver which results in a 44% increase in the life span of laboratory animals, is the re-emergence of this company’s visibility since its failed (but half-hearted) venture to market a resveratrol pill. GlaxoSmithKline, the parent to Sirtris, abandoned further research and development for its SRT501 resveratrol (rez-vair-ah-trol) drug when mega-doses induced kidney failure in a human trial among bone marrow cancer patients.

The quest to develop these small-molecule drugs began in 2003 when Harvard researchers linked a resveratrol, a red wine molecule, with a key gene — Sirtuin1 – thought to be activated in calorie restricted animals that results in prolongation of life span.

Read the whole post »